FIELD: biotechnology.
SUBSTANCE: methods include the next step: identification of binding specificity and/or affinity of many bispecific antibodies obtained by combining each element of the first plurality of antibody Fab-fragments or antibody scFv-fragments with each element of the second plurality of antibody Fab fragments or antibody scFv-fragments and with a linker, containing the second element of the first binding pair on its one end and the second element of the binding pair on its corresponding other end.
EFFECT: invention allows you to efficiently receive multispecific therapeutic molecules, such as bispecific antibodies, with the specified properties with regard to cell surface molecules on the cell of the patient, who is in need of treatment, or with regard to ligands, interacting with such cell surface molecule.
11 cl, 28 dwg, 8 tbl, 13 ex
Title | Year | Author | Number |
---|---|---|---|
BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE | 2012 |
|
RU2605390C2 |
METHOD FOR PRODUCTION AND SELECTION OF MOLECULES INCLUDING, AT LEAST TWO DIFFERENT GROUPS, AND APPLICATION THEREOF | 2013 |
|
RU2646159C2 |
ANTIBODIES WITHOUT Fc-FRAGMENT INCLUDING TWO FAB-FRAGMENT AND METHODS OF APPLICATION | 2012 |
|
RU2617970C2 |
UNIVERSAL TRANSMITTER MODULES THROUGH THE HEMATOENCEPHALITIC BARRIER | 2014 |
|
RU2799436C1 |
MONOVALENT CARRIER MODULES ACROSS BLOOD-BRAIN BARRIER | 2014 |
|
RU2694659C2 |
COVALENT BONDED POLYPEPTIDE TOXIN AND ANTIBODY CONJUGATES | 2014 |
|
RU2682754C2 |
CHIMERIC PROTEIN COMPOSED OF NGF ANTAGONIST DOMAIN AND TNFα ANTAGONIST DOMAIN | 2015 |
|
RU2678810C2 |
CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2011 |
|
RU2663123C2 |
CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2011 |
|
RU2774414C2 |
BIOSPECIFIC ANTIGEN-BINDING MOLECULES | 2012 |
|
RU2650775C2 |
Authors
Dates
2018-02-08—Published
2013-06-25—Filed